Balchem Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ted Harris

Chief executive officer

US$11.9m

Total compensation

CEO salary percentage	9.2%
CEO tenure	9yrs
CEO ownership	0.2%
Management average tenure	2yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ted Harris's remuneration changed compared to Balchem's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$109m
Sep 30 2023	n/a	n/a	US$103m
Jun 30 2023	n/a	n/a	US$99m
Mar 31 2023	n/a	n/a	US$99m
Dec 31 2022	US$12m	US$1m	US$105m
Sep 30 2022	n/a	n/a	US$109m
Jun 30 2022	n/a	n/a	US$109m
Mar 31 2022	n/a	n/a	US$102m
Dec 31 2021	US$6m	US$1m	US$96m
Sep 30 2021	n/a	n/a	US$93m
Jun 30 2021	n/a	n/a	US$90m
Mar 31 2021	n/a	n/a	US$88m
Dec 31 2020	US$5m	US$1m	US$85m
Sep 30 2020	n/a	n/a	US$83m
Jun 30 2020	n/a	n/a	US$82m
Mar 31 2020	n/a	n/a	US$81m
Dec 31 2019	US$4m	US$915k	US$80m
Sep 30 2019	n/a	n/a	US$80m
Jun 30 2019	n/a	n/a	US$78m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$3m	US$800k	US$79m
Sep 30 2018	n/a	n/a	US$100m
Jun 30 2018	n/a	n/a	US$97m
Mar 31 2018	n/a	n/a	US$94m
Dec 31 2017	US$2m	US$700k	US$90m

Compensation vs Market: Ted's total compensation ($USD11.95M) is above average for companies of similar size in the German market ($USD2.56M).

Compensation vs Earnings: Ted's compensation has increased by more than 20% in the past year.

CEO

Ted Harris (58 yo)

9yrs

Tenure

US$11,948,265

Compensation

Mr. Theodore L. Harris, also known as Ted, has been the Chief Executive Officer and President at Balchem Corporation since April 28, 2015. He serves as an Independent Director of Pentair Plc since April 30...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Theodore Harris	Chairman	9yrs	US$11.95m	0.21% $ 8.6m
Carl Bengtsson	Executive VP	5.2yrs	US$1.67m	0.061% $ 2.6m
Hatsuki Miyata	Executive VP	1.8yrs	US$1.15m	0.018% $ 736.4k
Jonathan Griffin	Senior Vice President of Corporate Development	less than a year	US$1.01m	0.039% $ 1.7m
Martin Reid	Senior VP & Chief Supply Chain Officer	3.3yrs	US$1.10m	0.020% $ 846.8k
William Backus	VP & Chief Accounting Officer	12.8yrs	US$960.42k	0.018% $ 770.0k
Michael Sestrick	Senior VP & CTO	1.6yrs	no data	0.021% $ 877.1k
M. Tignor	Senior VP & Chief Human Resources Officer	2.2yrs	no data	0.026% $ 1.1m
Frederic Boned	Senior VP and GM of Human Nutrition & Health	1.4yrs	no data	0.016% $ 692.7k
Job L. Gunsteren	Senior VP & GM of Specialty Products	1.6yrs	no data	no data

2.0yrs

Average Tenure

47yo

Average Age

Experienced Management: BL9B's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Theodore Harris	Chairman	9yrs	US$11.95m	0.21% $ 8.6m
Daniel Knutson	Independent Director	6.2yrs	US$220.30k	0.016% $ 657.4k
David Fischer	Independent Director	13.6yrs	US$205.80k	0.043% $ 1.8m
Matthew Wineinger	Lead Independent Director	8.6yrs	US$216.46k	0.019% $ 802.3k
Olivier Rigaud	Independent Director	less than a year	no data	0.0017% $ 70.1k
Joyce Lee	Independent Director	4.6yrs	US$205.80k	0.0086% $ 361.2k
Kathleen Fish	Independent Director	2.8yrs	US$204.80k	0.0049% $ 205.4k
Monica Vicente	Independent Director	less than a year	no data	0.0017% $ 70.1k

5.4yrs

Average Tenure

58.5yo

Average Age

Experienced Board: BL9B's board of directors are considered experienced (5.4 years average tenure).

Balchem Management

Management criteria checks 1/4

Key information

Recent management updates

Balchem Corporation, Annual General Meeting, Jun 20, 2024

Chairman recently sold €4.2m worth of stock

Independent Director recently sold €465k worth of stock

Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023

Senior VP & CTO recently sold €273k worth of stock

Independent Director recently sold €356k worth of stock

Recent updates

Balchem Corporation, Annual General Meeting, Jun 20, 2024

Balchem Corporation to Report Q1, 2024 Results on May 03, 2024

Chairman recently sold €4.2m worth of stock

Full year 2023 earnings released: EPS: US$3.38 (vs US$3.29 in FY 2022)

Balchem Corporation to Report Q4, 2023 Results on Feb 16, 2024

Now 21% overvalued after recent price rise

Upcoming dividend of US$0.79 per share at 0.6% yield

Balchem Corporation Announces Dividend, Payable on January 19, 2024

Third quarter 2023 earnings released: EPS: US$0.90 (vs US$0.79 in 3Q 2022)

Balchem Corporation to Report Q3, 2023 Results on Oct 27, 2023

Independent Director recently sold €465k worth of stock

Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023

Second quarter 2023 earnings released: EPS: US$0.94 (vs US$0.93 in 2Q 2022)

Balchem Corporation to Report Q2, 2023 Results on Jul 28, 2023

Senior VP & CTO recently sold €273k worth of stock

First quarter 2023 earnings released: EPS: US$0.71 (vs US$0.90 in 1Q 2022)

Independent Director recently sold €356k worth of stock

Full year 2022 earnings released: EPS: US$3.25 (vs US$2.98 in FY 2021)

Balchem Corporation to Report Q4, 2022 Results on Feb 24, 2023

Upcoming dividend of US$0.71 per share

Balchem Corporation Announces Dividend, Payable on January 20, 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$0.78 in 3Q 2021)

Insufficient new directors

Balchem Corporation to Report Q3, 2022 Results on Nov 04, 2022

Insufficient new directors

James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, Notifies Balchem Corporation His Intent to Retire from His Role

Insider recently sold €173k worth of stock

Second quarter 2022 earnings released

Balchem Corporation to Report Q2, 2022 Results on Jul 29, 2022

Balchem Corporation (NasdaqGS:BCPC) completed the acquisition of Kappa Bioscience AS from Verdane Edda managed by Verdane and others on June 21, 2022.

Balchem Corporation (NasdaqGS:BCPC) entered into an agreement to acquire Kappa Bioscience AS from Verdane Edda managed by Verdane and others.

Balchem Corporation Announces Resignation of Mark Stach as Company Secretary

Balchem Corporation, Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.73 in 1Q 2021)

Balchem Corporation to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Balchem Corporation to Report Q4, 2021 Results on Feb 18, 2022

Upcoming dividend of US$0.64 per share

Third quarter 2021 earnings released: EPS US$0.78 (vs US$0.67 in 3Q 2020)

Insider recently sold €946k worth of stock

Second quarter 2021 earnings released: EPS US$0.70 (vs US$0.66 in 2Q 2020)

Balchem Corporation(NasdaqGS:BCPC) dropped from Russell 3000E Value Index

Independent Director Paul Coombs has left the company

Independent Director Paul Coombs has left the company

First quarter 2021 earnings released: EPS US$0.73 (vs US$0.61 in 1Q 2020)

New 90-day high: €107

Full year 2020 earnings released

Revenue beats expectations

Paul Coombs Not Stands for Re-Election as Member of Class 2 of the Board of Balchem Corporation

Balchem Corporation to Report Q4, 2020 Results on Feb 19, 2021

New 90-day high: €94.60

New 90-day high: €91.00

Insider recently sold €261k worth of stock

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Balchem Corp Announces Retirement of Scott Mason, Vice President of Manufacturing and Supply Chain and Vice President and General Manager, Industrial Products

Balchem Corporation to Report Q3, 2020 Results on Oct 28, 2020

New 90-day high: €90.10

New 90-day low: €79.05

Balchem Corporation to Report Q2, 2020 Results on Jul 31, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members